Heparin drugs are widely used in hemodialysis and various surgical operations. Compared with unfractionated heparin, low-molecular-weight heparin has the following advantages: no need to monitor thrombin time; smaller potential bleeding risk; smaller osteoporosis risk after long-term use; smaller risk of inducing thrombopenia.
Low-molecular-weight heparin preparations are gradually replacing unfractionated heparin preparations because of wider clinical applications. The main product of low-molecular-weight heparin preparations is Enoxaparin Sodium which was originally developed by Aventis (merged with Sanofi later) and approved to be sold in the trade name of Lovenox in 1993. Sanofi’s Enoxaparin Sodium Injection was approved by FDA in Oct. 2004, and entered the Chinese market in the beginning of 2005 with a continuous growth in market size. Its sales value exceeded CNY 300 million in 2017.
Enoxaparin Sodium can be used to prevent deep vein thrombosis and pulmonary embolism, to treat established venous thrombosis, to prevent thrombus formation in extracorporeal circulation during hemodialysis, and to treat unstable angina and non-Q-wave myocardial infarction.
According to CRI, generic drugs also takes up some market share because the average price of Sanofi’s products is comparatively high. Many pharmaceutical enterprises in China have obtained the production permit for Enoxaparin Sodium injection. CRI’s market research shows that the Chinese market is dominated by Sanofi. Other major market players include Hangzhou Jiuyuan Gene Engineering Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., etc. In 2017, the top 5 manufacturers took up over 90% market share by sales value, with Sanofi’s market share reaching approximately 80%. Sanofi’s market share is gradually flowing to domestic enterprises because of high average price. It is estimated that Sanofi will have ever smaller market share in the coming years with more Enoxaparin Sodium manufacturers entering the market in China.
According to CRI, as China’s population ages, the incidence of vascular embolic disease continues to rise. At the same time, as the incidence of ESRD in China continues to rise, the number of people receiving hemodialysis is also rising. All these factors have driven the growth of the Enoxaparin Sodium market. There is still a large growth potential for the Chinese Enoxaparin Sodium market.
-Incidence of thrombosis in China
-Development history of Enoxaparin Sodium in China
-Sales of Enoxaparin Sodium in China
-Prices of Enoxaparin Sodium in China
-Major Enoxaparin Sodium manufacturers in China
-Prospects of Chinese Enoxaparin Sodium Market